NewAmsterdam Pharma Co N.V. (NAMS) stock
Close on Nov 13, 2026Market cap $2.41BP/E –Yield –
NewAmsterdam Pharma Co N.V. saw revenue fall 26.4% to $25.94M over the twelve months to Sep 30, 2026. Free cash flow was -$150.86M. At the latest close the market valued the company at $2.41B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.41B
- P/E ratio
- –
- Price to sales
- 92.82
- Price to book
- 3.82
- Dividend yield
- –
- Free cash flow yield
- -6.27%
Fundamentals
- Revenue
- $25.94M
- Net income
- -$204.89M
- EPS, diluted
- -$1.68
- Free cash flow
- -$150.86M
- Book value per share
- $5.08
- Diluted shares
- 124M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $19.97
- Open
- $19.93
- Day's range
- $19.48 – $20.62
- Volume
- 1,674,281
- Average volume (20 days)
- 1,758,022
- Beta (5 years)
- 0.83
- 52-week range
- $17.90 – $42.20
- RSI (14 days)
- 47.3
- Volatility (1 year)
- 53.9%
- Relative volume
- 1.16×
- WACC
- 9.2%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NAMS | S&P 500 | Difference | NAMS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.2% | -3.0% | +2.8 pts | ||
| 3 months | -24.5% | -2.8% | −21.7 pts | ||
| Year to date | -42.6% | +11.5% | −54.1 pts | ||
| 1 year | -44.7% | +13.5% | −58.2 pts | ||
| 3 years | +116.6% | +77.7% | +38.9 pts | +29.4% | +21.1% |
| 5 years | +105.1% | +72.6% | +32.5 pts | +15.4% | +11.5% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NewAmsterdam Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- Results
- Update
- Results
About NewAmsterdam Pharma
Pharmaceutical Preparations
This late-stage biopharmaceutical company focuses on developing therapies for cardiometabolic disorders in patient groups with inadequate or poorly tolerated existing treatment options. Its primary candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor investigated as a once-daily monotherapy or in a fixed-dose combination with ezetimibe. These investigational therapies serve as adjuncts to statin regimens to lower low-density lipoprotein cholesterol in individuals at risk of cardiovascular disease, atherosclerotic cardiovascular disease, and heterozygous familial hypercholesterolemia.
Company profile, executives and historyNewAmsterdam Pharma stock: common questions
What is NewAmsterdam Pharma's stock price?
NAMS closed at $20.14 on Nov 13, 2026, up 0.85% on the day. Over the past 52 weeks it traded between $17.90 and $42.20.
What is NewAmsterdam Pharma's market cap?
NewAmsterdam Pharma was worth $2.41B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is NAMS's P/E ratio?
NewAmsterdam Pharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.68), so it has no meaningful P/E ratio.
How much revenue does NewAmsterdam Pharma make?
NewAmsterdam Pharma reported revenue of $25.94M for the twelve months to Sep 30, 2026, down 26.4% from a year earlier.
Does NewAmsterdam Pharma pay a dividend?
No. NewAmsterdam Pharma has not paid a cash dividend over the last twelve months.
When does NewAmsterdam Pharma report earnings next?
NewAmsterdam Pharma's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has NAMS stock performed over the past year?
Including dividends, NAMS returned -44.7% over the past year, against +13.5% for the S&P 500.
Who are NewAmsterdam Pharma's competitors?
Companies most similar to NewAmsterdam Pharma by business, industry and size include VTVT, PRQR, ZNTL, VRDN, LXRX.
See a number that looks wrong?